Patients hospitalized for community-acquired pneumonia present reduced functional performance

Anderson José Simone D. Corso

Abstract

BACKGROUND:

Symptoms of fatigue and dyspnea, treatment with oral corticosteroids, high circulating levels of cytokines, and oxidant/antioxidant imbalance in patients hospitalized with community-acquired pneumonia (CAP) could affect the patients' exercise tolerance and peripheral muscle strength (PMS).

OBJECTIVE:

To evaluate the functional capacity (FC) of patients hospitalized for CAP and to correlate the FC with length of hospital stay.

METHOD:

We prospectively evaluated 45 patients (49±16 years; CAP group) and 20 healthy subjects (53±17 years; control group). They were randomized to perform, on separate days, a 6-minute walk test (6MWT), a test of PMS, and the Glittre test (GT). Additionally, the SF-36 questionnaire and the MRC scale were completed and evaluated.

RESULTS:

There were significant differences between the groups (CAP and controls) for the 6MWT (381.3±108 vs. 587.1±86.8 m) and GT (272.8±104.3 vs. 174±39 sec). The CAP group also presented worse health-related quality of life (HRQoL) scores, reduced strength (quadriceps and biceps), and higher scores of dyspnea. The time required to perform the GT correlated with the length of hospital stay (r=0.35, P=0.02) and dyspnea (r=0.36, P=0.02). Significant correlations were observed between GT and 6MWT (r=-0.66, P=0.0001) and between GT with the physical functioning domain of SF-36 (r=-0.51, P=0.0001).

CONCLUSIONS:

Patients hospitalized for CAP presented with reduced FC, PMS, and HRQoL during hospitalization. In addition, GT performance was related to the length of hospital stay.

pneumonia; physical therapy; exercise tolerance; quality of life; muscle strength


Introduction

Community-acquired pneumonia (CAP) is one of the most common and serious acute lung diseases. There are 5.6 million cases of CAP are diagnosed annually worldwide, and 1.1 million of these require hospitalization1-3. The morbidity and treatment costs of CAP have a substantial social and economic impact4.

CAP is an acute inflammatory disease affecting the lungs. The clinical findings are cough, sputum production, chest pain, tachypnea, and fever. Other systemic manifestations, such as generalized myalgia, anorexia, nausea, vomiting, diarrhea, and sensory abnormalities, may also be observed1,5. The combination of respiratory and systemic symptoms contributes to malaise and severe prostration. Previous studies have shown that moderate to severe fatigue and dyspnea were the most commonly reported symptoms when CAP was diagnosed. The symptoms remained for seven days and could persist for up to 90 days6. High levels of inflammatory markers were found in patients hospitalized with CAP and were related to functional impairment, which was evaluated using a scale of daily activities7.

Symptoms of fatigue and dyspnea, treatment with oral corticosteroids, high circulating levels of cytokines, and oxidant/antioxidant imbalance8 in patients hospitalized with CAP could affect the patients' exercise tolerance and muscle function. Therefore, we designed this study to investigate the functional capacity, peripheral muscle strength (PMS) and health-related quality of life (HRQoL) in patients hospitalized for CAP. In addition, we analyzed the correlation between the functional capacity tests and length of hospital stay.

Method

Study population

We evaluated 72 patients (44 men) who were hospitalized in a university-affiliated hospital. Inclusion criteria were: CAP as a cause of hospitalization, length of stay of less than 48 hours, over 18 years of age, hemodynamically stable, and an ability to walk and handle objects unassisted. CAP was diagnosed according to the Brazilian guidelines5 (newly acquired respiratory symptoms, cough, sputum production, dyspnea, fever, tachypnea, auscultatory findings of abnormal breath sounds and crackles and presence of new lung infiltrate in a chest radiograph). Patients with other pulmonary diseases (chronic obstructive pulmonary disease-COPD, asthma, bronchiectasis or cystic fibrosis) and orthopedic or neurological conditions were excluded. The control group consisted of 20 age and sex-matched healthy subjects recruited from the community.

All subjects signed the consent form, and the study was approved by the Ethics Committee on Research of Universidade Nove de Julho, São Paulo, SP, Brazil, protocol number 273811/2009.

Study design

This was a cross-sectional controlled study conducted on two consecutive days. On the first day, patients answered the Medical Research Council scale (MRC)9 and Short-Form 36 questionnaire (SF-36)10, and their CRB-65 scores11 were recorded. Subsequently, patients performed either a spirometry12,13 or peripheral muscle strength (PMS) test, as well as either the 6-minute walk test (6MWT)14,15 or the Glittre test (GT)16. On the second day, patients underwent the tests not performed on the previous day (spirometry or PMS and 6MWT or GT). The order of the tests was randomized (Figure 1).

Figure 1
Study flow diagram. CAP: community-acquired pneumonia; PMS: peripheral muscle strength; 6MWT: six minute walk test; GT: Glittre test.

Assessments

Peripheral muscle strength

We obtained the dominant-limb strength of the quadriceps femoris (QF) and biceps brachii (BB) using the maximum voluntary isometric contraction (MVIC) assessed with a dynamometer (model DLC/DN, Kratos, São Paulo, Brazil). Patients did three repetitions of MVICs maintained for 5 seconds, with a minute rest between them. If the difference in strength of the three contractions exceeded 5%, we conducted another measure of MVIC17. The highest value was recorded for analysis. For the QF, patients sat on a chair with the hip and knee at 90o flexion and were requested to extend the knee; for BB, the elbow joint was positioned at 90o flexion, and then elbow flexure was requested. The PMS measurement was performed in a subgroup of patients (n=28).

Glittre test

The GT was undertaken as previously described16. The test was conducted in a 10-meter-long hallway in the hospital. Two tests were performed an hour apart on the same day to minimize the learning effect previously demonstrated in patients with COPD16. The test with shorter duration was used for the analysis. Heart rate (HR), oxygen saturation (SpO2), dyspnea, and leg fatigue were measured at rest and at the end of the test. The time spent performing the test was recorded and was the main outcome for this test.

Analysis

We performed statistical analysis using SPSS for Windows version 17.0 (SPSS, Chicago, Illinois). We used the Kolmogorov-Smirnov test to verify the adherence of the data distribution to a normal curve. The parametric data (age, BMI, 6MWT, GT, PMS, pulmonary function and domains of physical functioning, bodily pain, general health perception, vitality, social functioning and mental health of the SF-36 questionnaire) were expressed as means and standard deviations (SD). Nonparametric data (length of hospital stay, MRC scale and the domains of physical role functioning and emotional role functioning of the SF-36 questionnaire) were expressed as medians and interquartile ranges. We performed parametric variable comparisons between the CAP and control groups using Student's t-test for independent samples. We compared the nonparametric variables with the Mann-Whitney test. Correlations between variables were performed using Pearson's correlation test. The probability of a type I error was set at 5% (P<0.05).

Results

Sample characteristics

From a sample of 72 patients with CAP, 27 were excluded, including 10 patients who were discharged before completing the survey, 7 who had other associated lung diseases (asthma and tuberculosis), 5 who decided to withdraw from the study, 3 who experienced technical problems during some evaluations, one who progressed to pulmonary thromboembolism and one who left the hospital before completing the study. No volunteers were excluded from the control group. Therefore, 65 subjects were surveyed in total, including 45 patients in the CAP group (28 men) and 20 subjects in the control group (10 men). There were no significant differences between the groups regarding age and BMI. Patients in the CAP group showed a restrictive pattern in lung function (Table 1).

Table 1
Characteristics of the CAP and control groups.

All hospitalized patients took antibiotics. In addition, 39 patients received gastric protectors, 20 used inhaled bronchodilators, 17 received corticosteroids, 16 received antihypertensive medications, 11 received antiplatelet medications, 8 received insulin, 6 received diuretics, and 9 received other medications. Four patients were given oxygen during the tests. The CRB-65 scores were 0 and 1 for 34 and 11 patients, respectively. Within the CAP group, 43 patients were discharged and two died.

Functional capacity and peripheral muscle strength

Patients with CAP walked less in the walking test and took longer to perform the GT (Table 2). Additionally, they had lower maximum heart rates. We observed a significant difference in SpO2 between the CAP and control groups. Compared to the control group, CAP patients showed reduced PMS for biceps (15.9±5.6 vs. 12.4±4.9 Kgf, P=0.031) and quadriceps (29±6.4 vs. 19±7.2 Kgf, P<0.001).

Table 2
Results of 6MWT and GT.

Dyspnea and health-related quality of life

Patients in the CAP group had high scores for dyspnea and reduced HRQoL compared to the control group (Table 3).

Table 3
Comparison between the CAP and control groups for dyspnea and HRQoL.

Correlations between FC, PMS and HRQoL

The time spent performing the GT was the only outcome that presented correlations with the length of hospital stay and MRC scale, as both variables did not show correlations with 6MWT (Figure 2). Longer times taken to perform the GT were correlated with lower distances walked in the 6MWT (r=-0.66; P=0.0001). Additionally, the GT correlated with the physical functioning domain of the SF-36 (r=-0.51, P<0.001) and with lung function (FEV1: r=-0.56, P=0.002; FVC: r=-0.53, P=0.0001).

Figure 2
Correlations between the length of hospital stay and GT/6MWT (A) and between MRC scale and GT/6MWT (B). A) Glittre test: black circles, solid line (r=0.35, P=0.02), 6MWT: white circles, dashed line (r=-0.2, P=0.19). B) Glittre test: black circles, solid line (r=0.36, P=0.02), 6MWT: white circles, dashed line (r=-0.16, P=0.28).

The 6MWT showed significant correlation with lung function (FEV1: r=0.56 and FVC: r=0.54; both P=0.0001). 6MWT also correlated positively with PMS (quadriceps: r=0.40, P=0.03) and HRQoL (bodily pain: r=0.43, P=0.004; physical functioning: r=0.35, P=0.02).

Discussion

CAP is a serious disease of high prevalence and is a major cause of hospitalization around the world. It generates high costs and is the leading cause of death from infectious diseases1-5. CAP's mortality rate has been the main focus of previous studies. However, its impact on functional status is rarely studied. The present study shows a reduction in FC, PMS, and HRQoL in patients hospitalized for CAP.

To the best of our knowledge, this is the first study that objectively evaluates functional capacity by performance-based tests such as the GT and 6MWT and peripheral muscle function by the maximum voluntary contraction in patients hospitalized for CAP.

6MWT is the most frequently used test of FC in patients with respiratory diseases because it has established reference values14-15,18 and has been considered the best marker of inactivity in daily living for patients with COPD19. However, the GT has been suggested as being more appropriate to assess functional status in patients with COPD because while the 6MWT evaluates only a single isolated activity, the GT involves unsupported arm activities, rising from a chair, walking, and climbing stairs20.

It has been demonstrated that GT performance time in patients with COPD is longer in comparison with a control group21. The time spent by patients with COPD to perform the GT was 60% greater than that in a control group21, which is similar to the percentage (64%) difference found in our study when comparing the CAP and control groups. It is interesting to note that our patients with CAP had similar times for performing the GT compared with patients with COPD in this other study16 (272.8 sec and 280.2 sec, respectively). Therefore, CAP patients demonstrate difficulties in performing simple and routine activities similar to activities of daily living (ADL). The poor performance of our younger patients (49±16 yrs) with better lung function (FEV1: 57.8±17.8% of predicted) could be attributed to the acute clinical condition of patients hospitalized with CAP as compared to stable COPD patients (61±8 yrs, FEV1: 48±15% of predicted)16.

The GT is composed of a circuit of functional activities that the patient needs to accomplish as fast as possible. These activities were developed to represent essential activities that are common in everyday life and known to be problematic for patients with pulmonary disease, particularly patients with COPD. In our study, the GT was the only test that correlated with the length of hospital stay and dyspnea evaluated by the MRC scale. In Skumlien's study, significant relationships were observed between the GT and disease stage (r=-0.61; p<0.01), hospitalization rate in the past year (r=0.35; p<0.01), exercise capacity (r=-0.82; p<0.01), reported activity restrictions (r=0.43; p<0.01), dyspnea during daily activities (r=0.35; p<0.01) and BMI (r=-0.57; p<0.01)16. Additionally, patients with longer GT times had a five times the risk of three or more serious exacerbations compared to those with shorter GT times. Thus, the authors suggested that the GT yields information complementary to the 6MWT16. This seems reasonable because the 6MWT uses only the act of walking, which is not representative of the metabolic expenditure and dyspnea induced by the different ADL provided by the GT21. Based on these considerations, it is possible that the GT is more suitable for the FC evaluation in patients hospitalized for CAP. Although our findings demonstrate that the GT was the only test of FC that correlated with length of stay, future studies are recommended to confirm whether this test is more sensitive in detecting the reduction of FC with this condition.

Patients hospitalized for CAP presented lower performance on the 6MWT (66% of predicted), indicating a reduction in FC, as previously demonstrated in patients with stable COPD22-24. In a study by Solh et al.7, elderly patients hospitalized for CAP showed a decline in functional capacity as assessed by an ADL scale. This decline was related to the level of tumor necrosis factor (TNF-alpha) and the severity of the CAP. Persistent FC decline was observed after three months and was associated with hospital readmission and death, which leads us to infer that exercise training should be applied early to minimize the loss of FC and PMS during hospitalization. In our sample, the CRB-65 scores were low, such that the patients could perform all the proposed assessments. Consequently, the majority of patients evolved favorably, culminating with discharge from the hospital.

Our study is the first to evaluate PMS in patients hospitalized for CAP. We were interested in studying this outcome because patients with CAP have high levels of inflammatory cytokines7,25-27 and unbalanced oxidant/antioxidant ratios in favor of the oxidants8, which are not related to the disease severity scores28. It is possible that inflammatory and oxidative stress are involved in the development of peripheral muscle weakness during hospitalization in patients with CAP, as previously demonstrated in patients with COPD29-31.

Reduced FC and PMS led to difficulty in performing ADL, compromising all domains measured by the SF-36 questionnaire. Our results are in agreement with those of Metlay et al.6, who evaluated the SF-36 in patients with CAP and found similar scores for all SF-36 domains except the vitality and emotional role functioning.

Implications of the study

Our results highlight the need to assess FC and PMS not only in patients with COPD hospitalized due to acute exacerbation but also in patients with acute pulmonary disease, in order to diagnose their FC and muscle impairment. Strategies to minimize the functional and peripheral muscle impairment through resistance training should be tested in patients with CAP, as resistance training has been effective in preventing the deleterious impact of exacerbations on peripheral muscle function in patients with COPD32.

Limitations of the study

This study has some relevant limitations. Patients did not undergo an evaluation before discharge or in the period after hospital discharge. However, comparisons with the control group allowed us to confirm impairments of FC, PMS, and HRQoL in patients hospitalized with CAP. It is possible that the reductions in FC could have been overestimated, as the control group was composed of healthy individuals instead of hospitalized controls. However, it is difficult to establish a hospitalized healthy control group because any reason for hospitalization could indicate a prior reduction of the outcomes evaluated in our study. We did not objectively measure patients' physical activity during hospitalization with any activity monitors, nor did we measure their inflammatory status, both of which could explain the reduced PMS in our patients.

Conclusion

Patients hospitalized for CAP have reduced functional capacity, peripheral muscle strength, and health-related quality of life during hospitalization. The GT was the only functional capacity test that demonstrated a correlation with the length of hospital stay. New therapeutic approaches applied to hospitalized patients should be studied to maintain and/or restore functional capacity and peripheral muscle strength in these patients.

Acknowledgments

We express our gratitude to the physical therapy students who assisted with this research for their assistance in conducting the data collection (André Ferreira da Silva, Angra Caicó de Lima, Áurea Josiane Reises da Silva, Carlos André Batistela, Carina Santos Silva Mori, Danielle Fortunato da Silva, Marcia Gonçalves da Silva Reis, Maria Aparecida Martins de Macedo, Paula Fernanda Marques de França, Raiene Campos Caminha and Valdete da Costa Veiga).

References

  • 1
    Niederman MS, Mandell LA, Anzueto A. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-54. PMid:11401897. http://dx.doi.org/10.1164/ajrccm.163.7.at1010
    » http://dx.doi.org/10.1164/ajrccm.163.7.at1010
  • 2
    Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med. 1985;78(6B):32-7. http://dx.doi.org/10.1016/0002-9343(85)90361-4
    » http://dx.doi.org/10.1016/0002-9343(85)90361-4
  • 3
    Ross JS, Normand SL, Wang Y Ko DT, Chen J, Drye EE, et al. Hospital volume and 30-day mortality for three common medical conditions. N Engl J Med. 2010;362(12):1110-8. PMid:20335587 PMCid:PMC2880468. http://dx.doi.org/10.1056/NEJMsa0907130
    » http://dx.doi.org/10.1056/NEJMsa0907130
  • 4
    Niederman MS, McCombs JI, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20(4):820-37. http://dx.doi.org/10.1016/S0149-2918(98)80144-6
    » http://dx.doi.org/10.1016/S0149-2918(98)80144-6
  • 5
    Corrêa RA, Lundgren FLC, Pereira-Silva JL, Frare e Silva RL, Cardoso AP, Lemos AC, et al. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults. J Bras Pneumol. 2009;35(6):574-601. http://dx.doi.org/10.1590/S1806-37132009000600011
    » http://dx.doi.org/10.1590/S1806-37132009000600011
  • 6
    Metlay JP, Fine MJ, Schulz R, Marrie TJ, Coley CM, Kapoor WN et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med. 1997;12:423-30. PMid:9229281 PMCid:PMC1497132. http://dx.doi.org/10.1046/j.1525-1497.1997.00074.x
    » http://dx.doi.org/10.1046/j.1525-1497.1997.00074.x
  • 7
    Solh AE, Pineda L, Bouquin P, Mankowski C. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatrics. 2006;6:12. PMid:16899118 PMCid:PMC1557854. http://dx.doi.org/10.1186/1471-2318-6-12
    » http://dx.doi.org/10.1186/1471-2318-6-12
  • 8
    Katsoulis K, Kontakiotis T, Baltopoulos G, Kotsovili A, Legakis IN. Total antioxidant status and severity of community-acquired pneumonia: are they correlated? Respiration. 2005;72:381-7. PMid:16088281. http://dx.doi.org/10.1159/000086252
    » http://dx.doi.org/10.1159/000086252
  • 9
    Kovalis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validation of the modified pulmonary functional status and dyspnea questionnaire and the medical research council scale for use in Brazilian patients with chronic obstructive pulmonary disease. J Bras Pneumol. 2008;34(12):1008-18. http://dx.doi.org/10.1590/S1806-37132008001200005
    » http://dx.doi.org/10.1590/S1806-37132008001200005
  • 10
    Ciconelli RM, Ferraz MB, Santos WA, Meinão I, Quaresma MR. Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol. 1999;39(3):43-50.
  • 11
    Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax. 2007;62(3):253-9. PMid:16928720 PMCid:PMC2117168. http://dx.doi.org/10.1136/thx.2006.067371
    » http://dx.doi.org/10.1136/thx.2006.067371
  • 12
    Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para testes de função pulmonar. J Bras Pneumol. 2002;28(S3):S44-S58.
  • 13
    Pereira CAC, Barreto SP, Simões JG, Pereira FWL, Gerstler JG, Nakatani J. Reference values for spirometry in Brazilian adults. J Bras Pneumol. 1992;18(1):10-22.
  • 14
    American Thoracic Society. Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. PMid:12091180. http://dx.doi.org/10.1164/ajrccm.166.1.at1102
    » http://dx.doi.org/10.1164/ajrccm.166.1.at1102
  • 15
    Enright PL, Sherril DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5Pt1):1384-7. PMid:9817683. http://dx.doi.org/10.1164/ajrccm.158.5.9710086
    » http://dx.doi.org/10.1164/ajrccm.158.5.9710086
  • 16
    Skumlien S, Hagelund T, Børtuft Ø, Ryg MS. A field test of functional status as performance of activities of daily living in COPD patients. Respiratory Medicine. 2006;100(2):316-23. PMid:15941658. http://dx.doi.org/10.1016/j.rmed.2005.04.022
    » http://dx.doi.org/10.1016/j.rmed.2005.04.022
  • 17
    Mathur S, Eng JJ, MacIntyre DL. Reliability of surface EMG during sustained contractions of the quadriceps. J Electromyogr Kinesiol. 2005;15(1):102-10. PMid:15642658. http://dx.doi.org/10.1016/j.jelekin.2004.06.003
    » http://dx.doi.org/10.1016/j.jelekin.2004.06.003
  • 18
    Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14(2):270-4. PMid:10515400. http://dx.doi.org/10.1034/j.1399-3003.1999.14b06.x
    » http://dx.doi.org/10.1034/j.1399-3003.1999.14b06.x
  • 19
    Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972-7. PMid:15665324. http://dx.doi.org/10.1164/rccm.200407-855OC
    » PMid:15665324. http://dx.doi.org/10.1164/rccm.200407-855OC
  • 20
    Dechman G, Scherer SA. Outcome measures in cardiopulmonary physical therapy: focus on the Glittre-ADL test for people with chronic obstructive pulmonary disease. Cardiopulm Phys Ther J. 2008;19(4):115-8. PMid:20467508 PMCid:PMC2845232.
  • 21
    Corrêa KS, Karloh M, Martins LQ, Dos Santos K, Mayer AF. Can the Glittre ADL test differentiate the functional capacity of COPD patients from that of healthy subjects? Rev Bras Fisioter. 2011;15(6):467-73. PMid:22094546. http://dx.doi.org/10.1590/S1413-35552011005000034
    » http://dx.doi.org/10.1590/S1413-35552011005000034
  • 22
    Bernstein ML, Despars JA, Singh NP, Avalos K, Stansbury DW, Light RW. Re-analysis of the 12 minute walk in patients with COPD. Chest. 1994;105:163-7. PMid:8275726. http://dx.doi.org/10.1378/chest.105.1.163
    » http://dx.doi.org/10.1378/chest.105.1.163
  • 23
    Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with COPD. Am J Respir Crit Care Med. 1998;158:1185-9. PMid:9769280. http://dx.doi.org/10.1164/ajrccm.158.4.9802091
    » http://dx.doi.org/10.1164/ajrccm.158.4.9802091
  • 24
    Mantoani LC, Hernandes NA, Guimarães MM, Vitorasso RL, Probst VS, Pitta F. Does the BODE index reflect the level of physical activity in daily life in patientswith COPD? Rev Bras Fisioter. 2011;15(2):131-7. PMid:21789363. http://dx.doi.org/10.1590/S1413-35552011000200008
    » http://dx.doi.org/10.1590/S1413-35552011000200008
  • 25
    Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995;107:1342-9. PMid:7750329. http://dx.doi.org/10.1378/chest.107.5.1342
    » http://dx.doi.org/10.1378/chest.107.5.1342
  • 26
    Glynn P, Coakley R, Kilgallen I, Murphy N, Neill S. Circulating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax. 1999;54:51-5. PMid:10343632 PMCid:PMC1745351. http://dx.doi.org/10.1136/thx.54.1.51
    » http://dx.doi.org/10.1136/thx.54.1.51
  • 27
    Moussa K, Michie HJ, Cree IA, McCafferty AC, Winter JH, Dhillon DP, et al. Phagocyte function and cytokine production in community-acquired pneumonia. Thorax. 1994;49:107-11. PMid:8128397 PMCid:PMC474318. http://dx.doi.org/10.1136/thx.49.2.107
    » http://dx.doi.org/10.1136/thx.49.2.107
  • 28
    Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. EurRespir J. 2002;20:990-5. http://dx.doi.org/10.1183/09031936.02.00295102
    » http://dx.doi.org/10.1183/09031936.02.00295102
  • 29
    American Thoracic Society and European Respiratory Society Statement. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(4Pt2):S1-S40. PMid:10194189.
  • 30
    Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58(9):752-6. PMid:12947130 PMCid:PMC1746817. http://dx.doi.org/10.1136/thorax.58.9.752
    » http://dx.doi.org/10.1136/thorax.58.9.752
  • 31
    Abdullah AE, Ionescu AA, Nixon LS, Lewis-Jenkins V, Mathews SB, Griffiths TL, et al. Inflamatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(8pt1):1414-8. PMid:11704588. http://dx.doi.org/10.1164/ajrccm.164.8.2008109
    » http://dx.doi.org/10.1164/ajrccm.164.8.2008109
  • 32
    Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:1072-7. PMid:20133927. http://dx.doi.org/10.1164/rccm.200908-1203OC
    » http://dx.doi.org/10.1164/rccm.200908-1203OC

Publication Dates

  • Publication in this collection
    01 Aug 2013
  • Date of issue
    July-Aug 2013

History

  • Received
    27 Aug 2012
  • Reviewed
    13 Dec 2012
  • Accepted
    20 Feb 2013
Associação Brasileira de Pesquisa e Pós-Graduação em Fisioterapia Rod. Washington Luís, Km 235, Caixa Postal 676, CEP 13565-905 - São Carlos, SP - Brasil, Tel./Fax: 55 16 3351 8755 - São Carlos - SP - Brazil
E-mail: contato@rbf-bjpt.org.br